Purine and pyrimidine ribonucleoside monophosphate patterns of peripheral blood and bone marrow cells in human acute leukemias
Scavennec, J.; Maraninchi, D.; Gastaut, J.A.; Carcassonne, Y.; Cailla, H.L.
Cancer Research 42(4): 1326-1330
1982
ISSN/ISBN: 0008-5472 PMID: 6277481 Document Number: 196451
Purine and pyrimidine ribonucleoside monophosphate (NMP) levels were measured in blood and/or bone marrow cells of groups of patients with acute leukemia including acute lymphoblastic leukemia (ALL), acute nonlymphoblastic leukemia (ANLL) (acute myeloblastic, promyelocytic, myelomonocytic, and monoblastic leukemia). Patients were either untreated or in remission (17 with ANLL and 6 with ALL); 3 relapsed patients with ALL were also studied. Phytohemagglutinin-stimulated tonsil lymphocytes and bone marrow cells from normal subjects were used as controls. Observations in acute leukemias were compared with those in chronic leukemias. The cytidine, adenosine, guanosine and uridine 2'-, 3'- and 5'-monophosphate contents were measured by high-performance liquid chromatography. 2'- and 3'-NMP concentrations were 2.5 times higher in ALL and were 5.5 times higher, in ANLL leukemic cells than in chronic leukemic blood cells or control bone marrow cells. 2'-NMP were found only in leukemic blast cells and accounted for .apprx. 30% of 2'- and 3'-NMP mixtures. Levels of 2'- and 3'-NMP were around 2- and 4-fold higher in bone marrow than in peripheral blood cells of patients. The high level of 2'- and 3'-NMP found in bone marrow and blood cells of untreated ALL patients decreased during remission without reverting to normal whereas in relapse, it was 5-10 times higher than in the case of untreated patients. The 5'-NMP concentrations were always lower than those of 2'- and 3'-NMP and were the same in acute leukemias and control (including chronic leukemias). 5'-NMP levels remained constant during the course of the disease. 2'-and 3'-NMP levels appear to be useful markers of leukemic blasts and may facilitate both the diagnostic of acute leukemia and the monitoring of chemotherapy.